– USA, CA – Ambys Medicines, a cell and gene therapy company focused on advancing novel treatments to restore and regenerate liver function, today announced the appointment of Dr. Ronald Park, M.D., to its board of directors as the new CEO.
“We are excited to have found in Ron the ideal candidate to lead Ambys as CEO at this important time. Ambys has made significant progress over the past three years in advancing our novel liver-focused cell and gene therapy platforms, and we are about to enter a new phase as we work toward bringing our first allogeneic cell therapy product to the clinic,” said Board Chairman, Dr. Jeff Tong.
He added: “Ambys is pioneering a new approach to treating liver disease with tremendous potential. As we work to bring treatments to patients, Ron’s proven ability to drive results in complex new areas of high innovation, his leadership experience in drug development across the life cycle, and his personal experience having treated patients with severe liver disease will be a tremendous asset.”
About Dr. Ronald Park
Dr. Park is a highly regarded life sciences executive with broad executive leadership experience and a successful track record of driving results in pioneering fields and innovative situations. Before Ambys, he was EVP and General Manager for Health and DNA at Ancestry and held multiple roles at Roche and Genentech over a 17-year career, including co-Global Head and VP for Roche’s Personalized Healthcare Center of Excellence, General Manager for Denmark and Iceland, and Global Lifecycle Leader for Actemra. Earlier in his career, Dr. Park worked for McKinsey & Company and was on the faculty of UCLA as Assistant Professor of Internal Medicine. Throughout his 20-year career in the life sciences, he has worked in functional roles that have spanned the entire product lifecycle and on products that have achieved blockbuster status across multiple therapeutic areas. Dr. Park has also served on Boards for cell and gene therapy companies and consumer digital wellness.
“I treated many patients with the severe liver disease during my time as a physician, and I have always been struck by how terrible this disease is for both patients and their family members. It has been very difficult to advance new therapies for severe liver disease, and limited progress has been made since I treated these patients over 20 years ago. I am incredibly excited about the cutting-edge approach that Ambys is now taking, and I am inspired by its potential to revolutionize the way patients with severe liver disease are treated. I am also very impressed by the talented Ambys team, and I look forward to leading them to try to make a difference in the lives of millions of patients and their family members impacted by this disease,” said Dr. Park.
Dr. Park received his M.D. and M.B.A. from Stanford University and a B.A. with honors in Biology from Harvard.
About Ambys Medicines
Ambys Medicines is a cell and gene therapy company focused on discovering and developing regenerative and restorative therapies for patients with advanced liver disease. Ambys is pioneering the application of cell and gene therapy to meet the urgent need for novel treatments for those suffering from severe acute and chronic liver diseases. Ambys was launched in 2018 by Third Rock Ventures and Takeda Pharmaceuticals and is headquartered in South San Francisco, California.
For more information: https://www.ambys.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
